Novartis says 330 jobs hit as it closes MorphoSys sites
Releads with company statement
ZURICH, Dec 19 (Reuters) -Swiss pharmaceutical group Novartis NOVN.S said on Thursday it waswinding up MorphoSys sites in Germany and the United States, affecting 330 jobs.
Novartishad acquired MorphoSys atthe beginning of the year and said the move was part of an evaluation of its organisational setup and stemmed from its evolving research and development (R&D)
"We have communicated our intention to exit the MorphoSys sites in Munich and in Boston by end of 2025," a spokesperson said in an emailed statement to Reuters after a report in WirtschaftsWoche magazine.
"Approximately 330 roles were impacted, and all individuals were already communicated in mid-November," added the spokesperson, saying the company was committed to supporting the affected employees.
($1 = 0.9610 euros)
Reporting by Paul Arnold,
Writing by Friederike Heine and Madeline Chambers, Editing by Matthias Williams
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
